ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Phoenix, AZ

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Respiratory Tract Diseases
Rhinitis
Chronic Obstructive Pulmonary Disease
Dust Mite Allergy
Lung Diseases

Asthma trials near Phoenix, AZ, USA:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4)

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Active, not recruiting
Asthma Attack
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Peoria, Arizona, United States and 335 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Phoenix, Arizona, United States and 141 other locations

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma...

Enrolling
Asthma
Biological: NSI-8226
Biological: Placebo

Phase 2

Uniquity One (UNI)

Peoria, Arizona, United States and 73 other locations

PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, ...

Enrolling
Asthma
Other: Placebo
Drug: PF-07275315

Phase 2

Pfizer
Pfizer

Chandler, Arizona, United States of America and 124 other locations

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed repl....

Active, not recruiting
Asthma
Drug: BDA MDI HFO 160/180 μg
Drug: BDA MDI HFA 160/180 μg

Phase 3

AstraZeneca
AstraZeneca

Phoenix, Arizona, United States and 127 other locations

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated w...

Enrolling
Eosinophilic Asthma
Combination Product: Placebo for Benralizumab
Combination Product: benralizumab

Phase 3

AstraZeneca
AstraZeneca

Sun City, Arizona, United States and 148 other locations

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Phoenix, Arizona, United States and 75 other locations

levels compared with placebo in participants with moderate-to-severe asthma.Study participation will last approximately 65 weeks, including ...

Enrolling
Asthma
Drug: Brenipatide
Drug: Placebo

Phase 2

Lilly
Lilly

Tempe, Arizona, United States and 120 other locations

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compa...

Enrolling
Asthma
Drug: FF/VI
Device: ELLIPTA

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Paradise Valley, Arizona, United States and 41 other locations

safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma...

Active, not recruiting
Asthma
Drug: Placebo
Drug: Lunsekimig

Phase 2

Sanofi
Sanofi

Scottsdale, Arizona, United States of America and 161 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems